Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
RAPT Therapeutics ( (RAPT) ) has provided an announcement.
RAPT Therapeutics announced plans to initiate Phase 2b trials for RPT904 in food allergy by the second half of 2025 and Phase 2 or 3 trials for chronic spontaneous urticaria in 2026, projecting significant revenue potential in these markets. The company aims to offer improved dosing frequency and better compliance over existing treatments, positioning RPT904 as a potential best-in-class option, which could enhance their market presence and provide substantial commercial upside.
More about RAPT Therapeutics
RAPT Therapeutics, Inc. is a company focused on developing transformative therapies for high-value inflammatory diseases and oncology. They are actively working on drug candidates like RPT904, a ‘bio-better’ version of omalizumab for conditions such as food allergy (FA) and chronic spontaneous urticaria (CSU), as well as an oral CCR4 antagonist for Th2-driven disorders.
YTD Price Performance: -19.02%
Average Trading Volume: 3,358,558
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $46.14M
For a thorough assessment of RAPT stock, go to TipRanks’ Stock Analysis page.
